This grant is for developing innovative instrumentation and advanced analytical methods to address the escalating challenge of detecting emerging illicit drugs in the supply chain. Traditional testing strips are often insufficient for novel threats like Xylazine and nitazenes, for which specific strips may not exist. As these new substances continuously evolve and infiltrate real-world samples, there is a critical need for sensitive, and sample-agnostic analytical solutions. This funding aims to support research and development that goes beyond current limitations, enabling rapid and accurate identification of unknown or newly emerging drug compounds. The ultimate purpose is to enhance public health and safety by providing superior tools for comprehensive drug analysis, effectively mitigating future drug-related threats.
Opportunity ID: 356963
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-26-019 |
| Funding Opportunity Title: | Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 – Clinical Trials Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Use and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 04, 2024 |
| Last Updated Date: | Nov 04, 2024 |
| Original Closing Date for Applications: | Feb 19, 2025 |
| Current Closing Date for Applications: | Feb 19, 2025 |
| Archive Date: | Mar 27, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: See NOFO for further Eligibility Requirements. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples. Typically, testing strips are used to detect drug for which such strip exists, as the strips are fast, sensitive, low cost and reasonably accurate. However, as there might not be testing strips for the new threats, the analysis must be performed via sensitive and sample agnostic methods. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-019.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 356963 Full Announcement-RFA-DA-26-019 -> RFA-DA-26-019-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288462 | Jan 19, 2025 | Feb 19, 2025 | View |
Package 1
Mandatory forms
356963 RR_SF424_5_0-5.0.pdf
356963 PHS398_CoverPageSupplement_5_0-5.0.pdf
356963 RR_OtherProjectInfo_1_4-1.4.pdf
356963 PerformanceSite_4_0-4.0.pdf
356963 RR_KeyPersonExpanded_4_0-4.0.pdf
356963 RR_Budget_3_0-3.0.pdf
356963 RR_SubawardBudget30_3_0-3.0.pdf
356963 PHS398_ResearchPlan_5_0-5.0.pdf
356963 SBIR_STTR_Information_3_0-3.0.pdf
356963 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
356963 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
